We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,900
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Bipolar disorder proves to be a far more serious mental illness than previously thought due to high suicide rate, great functional impairments, and chronicity (Belmaker, 2004; Post et al., 1996). In patients with bipolar disorder, reduction of volume in specific brain areas has consistently been found (Drevets et al., 1997). Although pathophysiology of bipolar disorder is far from being clear, alterations in neuroprotective and neurotrophic signaling cascades are implicated in pathophysiology of bipolar disorder (Schloesser et al., 2008).

The original concept of the mood stabilizer was the agent that was effective in treating acute manic episodes and preventing their relapses, thus “stabilizing” the manic pole of bipolar disorder (Stahl, 2008). More recently, the concept of mood stabilizer has been broadened to include any drug to treat bipolar disorder (Stahl, 2008). Lithium and valproate are two of the most prominent drugs approved by the United States Federal Food and Drug Administration (FDA) used for the treatment of bipolar disorder. Since John Cade discovered the efficacy of lithium in the control of acute manic episode in 1948 (Cade, 1949), lithium has been a prototypic mood stabilizer. Lithium has also been found to be effective for the prevention of recurrent manic and depressive episodes and for augmenting the activity of classical antidepressants in some depressed patients (Baldessarini et al., 1999). Anticonvulsant mood stabilizers, of which structures are totally unrelated to lithium, are also efficacious for the treatment of bipolar disorder. However, despite the long history of use for the treatment of bipolar disorder, the mechanism of actions of mood stabilizers still remains obscure.

Mood stabilizers are known to possess neuroprotective and neurotrophic properties. It is well known that representative mood stabilizers, lithium and valproate regulate multiple target molecules in neuroprotective and neurotrophic signaling cascades. Major signaling cascades regulated by mood stabilizers are brain derived neurotrophic factor (BDNF) and extracellular signal-regulated kinase (ERK) pathways, glycogen synthase kinase-3 (GSK-3) mediated pathway, and regulating pathways for bcl-2 expression (Manji et al., 2000; Shaltiel et al., 2007). In addition, regulation of arachidonic acid cascade by mood stabilizers is considered to be another common mechanism of action of mood stabilizers (Rao et al., 2008).
Psychosocial stress is a predisposing and precipitating factor to mood disorders like depression and bipolar disorder. Psychosocial stress affects brain functions profoundly and stress response is mediated through interactions between brain areas implicated in pathophysiology of mood disorders (McEwen, 2004). Psychosocial stress, for example, contributes to depressive and anxious symptoms in patients with affective illness (Caspi et al., 2003; Hammen, 2005; Hammen et al., 2004; Melchior et al., 2007). Environmental and psychological stressors can recapitulate biochemical, structural, and behavioral aspects of depressive illness in laboratory animals (Pittenger & Duman, 2008). Substantial evidence indicates that neural plasticity induced by depression and chronic stress share common features. However, antidepressant treatment has shown to produce opposing effects to those induced by stress (Pittenger & Duman, 2008). Mood stabilizers also prevent stress-induced neural plasticity (Bachmann et al., 2005; Bourin et al., 2009). Moreover, external stress enhances apoptosis by decreasing antiapoptotic and increasing proapoptotic molecules (Kubera et al., 2011). These molecules are also the targets of mood stabilizers.

In the context of these overlapping signaling cascades involved in bipolar disorder, actions of mood stabilizers, and stress effect it is conceivable to infer that protection of stress-induced neural plasticity contributes to the mood stabilizing effect. In this chapter, protective effects of mood stabilizers against stress-induced neural plasticity (anti-stress effects) and their relevance to therapeutic effects will be discussed. For neuroprotective and neurotrophic properties of mood stabilizers, readers can refer to numerous excellent papers elsewhere.

2. Preventive effect of mood stabilizers on stress induced structural plasticity

Preventive effects on stress-induced structural plasticity seems to be centered on lithium, so in this section, stress-prevention effect will be focused on lithium.

2.1 The effect of lithium on structural plasticity in the hippocampus and prefrontal cortex

Stress effects on the brain have been most extensively studied in the hippocampus. The hippocampus is one of the key structures of the brain mediating the stress response. It has the highest density of stress hormone receptors, glucocorticoids and mineralocorticoids receptors in the brain with potent inhibitory influence on the activity of the hypothalamic-pituitary-adrenal axis. Morphology and functions of the hippocampus are altered by acute or chronic stress (Brunson et al., 2003; Buwalda et al., 2005; Mirescu & Gould, 2006). The morphological alterations and functional impairments of the hippocampus are observed in a number of mental illnesses such as mood disorders, posttraumatic stress disorder, schizophrenia, and Alzheimer’s disease (DeCarolis & Eisch, 2010). Sustained exposure to stress or glucocorticoids (GCs) leads to structural remodeling of the hippocampus with impairments in the performance of hippocampal-dependent cognitive functions (de Quervain et al., 1998; Magarinos & McEwen, 1995).

This structural remodeling effect is best studied in the CA3 region of the hippocampus. Sousa et al. (2000) reported that chronic stress or sustained GCs treatment induces structural remodeling in the CA1 as well as CA3 region with impairments in hippocampal-dependent
learning and memory functions. Reduction in the length and branch point of apical dendrites in the CA3 was observed following various types of stress. Daily restraint stress for 21 days or GCs exposure led to atrophy and the retraction of apical dendrites of CA3 pyramidal neurons in the rodent. Exposure to chronic psychosocial stress also resulted in structural remodeling of pyramidal neurons in the CA3 (Magarinos et al., 1996). This type of stress-induced structural plasticity is reversible because disrupted cellular morphology is slowly restored after cessation of stress without actual cell loss. Stress-induced dendritic atrophy in CA3 is mediated through decreased glucose uptake, increased glutamate and Ca$^{2+}$excitotoxicity, and decreased BDNF expression (Duman et al., 1999).

Chronic restraint stress results in the similar structural remodeling in the medial prefrontal cortex (mPFC) to that observed in the CA3 region of the hippocampus (Cook & Wellman, 2004; Radley et al., 2004). However, the apical dendritic atrophy following chronic stress is observed in the mPFC, but not in the orbital cortex (Liston et al., 2006), which suggests regional specificity of stress effect. Stress induces dendritic spine loss and altered patterns of spine morphology in the PFC in young rats, but not in aged rats (Bloss et al., 2011).

Lithium was found to prevent stress-induced dendritic atrophy of CA3 pyramidal neurons. Wood et al. (2004) reported that concomitant lithium treatment to rats prevented apical dendritic atrophy of CA3 pyramidal neurons caused by the exposure to restraint stress for 21 days with prevention of stress induced glutamatergic activation such as increase in glial glutamate transporter-1 mRNA expression and phosphorylation of cAMP response element binding protein (CREB) in the hippocampus. Alterations in cAMP signaling are implicated in mood disorders including bipolar disorder (Blendy, 2006; Karege et al., 2004). However, lithium treatment had no effect on dendritic morphology in non-stressed rats. Taken together, it is conceivable that lithium’s ability in preventing stress-induced dendritic remodelling and increased phosphorylation of CREB may contribute to its mood stabilizing efficacy.

### 2.2 The effect of lithium on structural plasticity in amygdala

Prolonged stress exposure induced increase in dendritic length and branching of principal cells in the amygdala, which is in contrast to dendritic remodeling found in the hippocampus and medial prefrontal cortex (Vyas et al., 2002). This stress-induced dendritic hypertrophy in the amygdala is associated with increased anxiety-like behavior (Vyas et al., 2006). Increase in the size and function of the amygdala was demonstrated in depression (Drevets, 2003). Functional and structural abnormalities in the amygdala have been implicated in bipolar disorder (Garrett & Chang, 2008). Increased amygdala activity was observed in manic and euthymic bipolar patients during emotional discrimination tasks (Yurgelun-Todd et al., 2000). The preventive effect of lithium on stress-induced dendritic remodeling was demonstrated in the amygdala as well. Johnson et al. (2009) investigated the stress effect and lithium’s effect on the dendritic morphology in the amygdala using the same study paradigm of Wood et al. (2004). They found that chronic lithium treatment prevented the stress-induced (restraint stress for 21 days) increase in dendritic length and branching of principal pyramidal neurons in the basolateral amygdala. However, like pyramidal neurons in CA3, lithium had no effect on dendritic morphology of the principal cells in the amygdala in non-stressed animals. This finding also suggests a specificity of neuroprotective action of lithium against stress.
2.3 The protective effect of lithium on stress-induced structural remodeling involves stabilization of glutamatergic activation

Lithium’s preventive effect on dendritic morphology is thought to be mediated at least by the decrease and stabilization of the stress induced glutamatergic activation. Several lines of evidence support this notion. First, the dendritic remodeling by chronic stress in the CA3 area was prevented with N-methyl-D-aspartate (NMDA) antagonist (Magarinos & McEwen, 1995) or dilantin which reduces glutamate release (Watanabe et al., 1992). In addition, dendritic atrophy of pyramidal neurons in the mPFC which occurs during restraint stress was prevented by the administration of a competitive NMDA antagonist, ±3-(2-carboxypiperazin-4-yl) propyl-1-phosphonic acid (CPP) (Martin & Wellman, 2011). Second, stress elevates extracellular glutamate level, thus facilitating glutamate signaling in the limbic brain. Chronic restraint stress, not acute stress, increases glutamate release and uptake in the hippocampus (Fontella et al., 2004; Lowy et al., 1993). Acute stress elevates extracellular glutamate level in the amygdala (Reznikov et al., 2007) and in the medial PFC (Moghaddam et al., 1994). Third, lithium is known to suppress glutamatergic signaling. Lithium treatment increases glutamate uptake into synaptosomes (Dixon & Hokin, 1998) and stimulates glutamate metabolism (Marcus et al., 1986). Fourth, lithium decreases the level of phosphorylation of NR2B subunit of NMDA receptor, thus suppressing the activity of NMDA receptor (Hashimoto et al., 2002). Lamotrigine which is an effective anticonvulsant mood stabilizer reduces glutamate release (E.S. Brown et al., 2010). These findings suggest that one of the key mechanisms of the therapeutic effect of lithium is the prevention of stress-induced dendritic remodelling by the stabilization of glutamate levels (Johnson et al., 2009).

3. The preventive effects of mood stabilizers on stress induced impairment in neurogenesis

3.1 Neurogenesis in the hippocampus

Neurogenesis in the adult brain has been found in most vertebrates including humans (Eriksson et al., 1998; Gould et al., 1999). Adult neurogenesis mainly occurs in the subgranular zone of the dentate gyrus in the hippocampus and subventricular zone of the ventricle wall (DeCarolis & Eisch, 2010). However, adult neurogenesis in the hippocampus is restricted to the subgranular zone of the dentate gyrus. Some researchers (Henn & Vollmayr, 2004) argue that impaired adult neurogenesis in the dentate gyrus may contribute to the reduced hippocampal volume in depressed patients although the contribution of neurogenesis in the dentate gyrus to the total volume of the hippocampus is considered very low in rodents and primates (Cameron & McKay, 2001; Kornack & Rakic, 1999). Adult neurogenesis is a multistep process. A brief description of adult neurogenesis is presented in this section (see Boku et al., 2010; Lucassen et al., 2010).

In the precursor cell phase, radial glia-like stem cells in the subgranular zone are, through transit amplifying cells, transformed to neural progenitor cells. Cell proliferation increases the number of neural progenitor cells. Cell fate determination is also believed to occur in transit amplifying cells. In the postmitotic cell phase progenitor cells are transformed to immature neurons in which axonal and dendritic extensions are initiated. These immature neurons are to be eliminated dramatically. This elimination process is apoptotic, NMDA
receptor-mediated and input dependent (Biebl et al., 2000; Kuhn et al., 2005; Tashiro et al., 2006). Surviving immature neurons migrate to the granular cell layer. Immature neurons mature with the maturation of dendritic spines. Newly formed mature neurons are finally incorporated to the hippocampal circuitry with projections to the CA3 neurons through mossy fiber pathway. These newborn granule cells have lower threshold for the induction of long term potentiation (LTP) and their survival depends on input dependent activity (Schmidt-Hieber et al., 2004). If integration to the pre-existing network does not occur, newborn cells are rapidly eliminated by apoptosis (Dayer et al., 2005).

3.2 The effect of mood stabilizers on stress-induced inhibition of neurogenesis in the hippocampus

Adult neurogenesis in the hippocampus is regulated by various environmental factors and age (J. Brown et al., 2003; Kempermann et al., 1997). With increasing age, adult neurogenesis rapidly declines (Manganas et al., 2007). Factors regulating adult neurogenesis include stress, exercise, dietary restriction, and an enriched environment. Stress is a potent negative regulator of adult neurogenesis (Boku et al., 2010). Exposure to both psychosocial and physical stressors inhibits one or more phases of adult neurogenesis (Czeh et al., 2002; Gould et al., 1997; Malberg & Duman, 2003; Pham et al., 2003). Various types of stress induce impairments of neurogenesis. Results obtained from several studies on the stress effects on adult neurogenesis are to be presented. Thomas et al. (2007) demonstrated that acute social dominance stress inhibited cell survival but not cell proliferation. Chronic intermittent restraint stress, but not acute stress, reduced progenitor cell proliferation without affecting levels of expression in BDNF, growth associated protein-43 (GAP-43), and synaptophysin (Rosenbrock et al., 2005). In learned helplessness, an animal model of depression induced by stress, stress acutely inhibits cell proliferation regardless of the induction of learned helplessness (Heine et al., 2004). Suppression of cell proliferation and enhanced apoptosis were noticed in the dentate gyrus of pups with maternal separation, which was reversed by fluoxetine treatment (Lee et al., 2001).

Mood stabilizers are known to prevent stress-induced reduction in neurogenesis, which requires multiple target molecules involving neuroprotective and neurotrophic signaling pathways. Chronic psychosocial stress in tree shrews reduced cell proliferation in the dentate gyrus and reduced hippocampal volume that were prevented by chronic treatment with an antidepressant, tianeptine (Czeh et al., 2001). Chronic mild stress (chronic mild stress) resulted in decrease in cell proliferation and differentiation, which was paralleled by depression-like behavior in forced swim test in rats. This chronic mild stress-induced decrease in neurogenesis was prevented by chronic lithium treatment. In addition, this effect was mediated at least through inhibition of glycogen synthase kinase-3β by lithium (Silva et al., 2008).

Chronic restraint stress induced suppression of cell proliferation which was accompanied by decreased expression of BDNF in the hippocampus (H. Xu et al., 2006). Boku et al. (2011) demonstrated that lithium and valproate, but not carbamazepine and lamotrigine, prevented the decrease in dentate gyrus-derived neural precursor cell proliferation induced by dexamethasone. However, all four mood stabilizers blocked apoptosis of dentate gyrus-derived neural precursor cells. This suggests that effects of mood stabilizers on adult neurogenesis in the dentate gyrus contribute to their therapeutic actions. This group also
showed that lithium reversed glucocorticoids-induced decrease in cell proliferation using dentate gyrus-derived neural precursor cells (Boku et al., 2010).

Interestingly, a study showed that treatment with valproate reduced cell proliferation in the subgranular zone of the dentate gyrus within the hippocampus, which was linked to significant impairment in their ability to perform a hippocampal-dependent spatial memory test. Contrary to expectation, valproate treatment caused a significant reduction in BDNF (Umka et al., 2010). But this study did not examine effects of valproate on neurogenesis under the stressed condition.

Stress-induced reduction in neurogenesis is also associated with reduction in vascular endothelial growth factor. Both angiogenesis and neurogenesis can be modulated by similar stimuli (Fabel et al., 2003). Vascular endothelial growth factor (VEGF) also has neurogenic effect (During & Cao, 2006; Silva et al., 2007). Chronic stress induces reduction in VEGF expression in the hippocampus (Heine et al., 2005; Silva et al., 2007) with concomitant reduction in proliferating cells (Heine et al., 2005). On the other hand, lithium treatment attenuated stress-induced reduction in VEGF expression and prevented stress-induced upregulation of GSK-3β and stress-induced β-catenin. These results suggest that protection by lithium against stress-induced impairment of neurogenesis can be mediated through the GSK-3β/β-catenin/VEGF signaling pathway (Silva et al., 2007).

Early life stress causes decrease and increase in cell proliferation and apoptosis respectively. Rat pups with maternal separation stress showed decreased cell proliferation and increased apoptosis, which was attenuated by concomitant fluoxetine treatment (Lee et al., 2001). In line with this, a study showed that early life stress effects could be counteracted by lithium treatment. Maternal deprivation induced stress decreased neuropeptide Y-like immunoreactivity in the hippocampus and striatum and increased neuropeptide Y-like immunoreactivity and corticotrophin releasing hormone-like immunoreactivity in the hypothalamus. Lithium treatment counteracted maternal deprivation effects by increasing neuropeptide Y-like immunoreactivity in the hippocampus and striatum and decreasing corticotrophin releasing hormone-like immunoreactivity in the hypothalamus (Husum & Mathe, 2002).

In addition to their preventive effect of lithium against stress-induced impairment of neurogenesis, lithium and valproate by themselves increase neurogenesis in the dentate gyrus of adult animals (G. Chen et al., 2000; Hao et al., 2004; Son et al., 2003). Neurogenesis promoting effect of lithium and valproate is ascribed to their capability to activate extracellular signal regulated kinase (ERK) signaling cascade (G. Chen et al., 2000; Hao et al., 2004).

4. The effect of mood stabilizers on stress-induced impairments in synaptic plasticity

Induction of hippocampal long term synaptic plasticity is profoundly affected by stress (Yang et al., 2004). It is well known that mild and transient stress enhances hippocampal-dependent learning and memory (Luine et al., 1996). However, exposure to more prolonged stress or severe stress definitely impairs hippocampal-dependent cognition (Sapolsky, 2003). Hippocampal-dependent learning and memory is also disrupted following chronic exposure to GCs or exposure to high dose of GCs (Joels, 2001). Stress-induced impairment of LTP is
considered to contribute to impaired hippocampal-dependent memory. Rats exposed to inescapable stress shows impairment in hippocampal-dependent memory and LTP and this impairment is mimicked by NMDA antagonist, (2R)-amino-5-phosphonovaleric acid (APV), injection into the dorsal hippocampus (Baker & Kim, 2002). Thus, the relationship between hippocampal-dependent cognitive performance and level of stress or GCs takes the inverted U pattern. Stress or GCs disrupts LTP in the various hippocampal subfields (Diamond & Park, 2000; Foy et al., 1987; Shors & Dryer, 1994; Shors et al., 1989). But similar stress paradigms resulting in impairment of LTP enhance long term depression (LTD) (L. Xu et al., 1997).

Inverted U pattern can also be applied to LTP, i.e. milder level of exposure to stress or GCs enhances LTP while more severe level of exposure to stress or GCs impairs LTP (Diamond et al., 1992; Pavlides et al., 1994). The mechanism underlying this inverted U pattern is ascribed to differential occupancy of mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). Under mild stress or low GCs condition, heavy occupancy or saturation of MR by GCs is believed to be responsible to enhancement of cognition and LTP (Sapolsky, 2003). Previous studies showed that MR occupancy enhances LTP (Pavlides et al., 1995; Vaher et al., 1994) and hippocampal-dependent spatial memory tasks (Oitzl et al., 1998).

The mechanism of LTP will be briefly described according the review by Pittenger and Duman (2008). Local elevation of cAMP and Ca$^{2+}$ induces short term synaptic plasticity, i.e. early LTP. Ca$^{2+}$ influx through NMDA receptors or voltage gated calcium channel activates Ca$^{2+}$/calmodulin dependent kinases (CaMK). Among them, Ca$^{2+}$/calmodulin dependent kinase II (CaMK II) is critical for early LTP. CaMK II and other CaMK phosphorylate the GluR 1 subunit of AMPA receptors, which renders AMPA receptors on the postsynaptic membrane potentiated in function. In addition, phosphorylation of AMPA receptors promotes insertion of AMPA receptors on the postsynaptic membrane. Once activated by local increase in Ca$^{2+}$, CaMK II phosphorylates itself persistently even after fall in local Ca$^{2+}$ level. Thus, this property of CaMK II makes CaMK II a suitable molecule for short term synaptic change. However, long term synaptic change requires other signaling pathways: cAMP-dependent protein kinase (PKA) and mitogen-activated protein kinase (MAPK) pathways. Stimulation of PKA and MAPK pathways results in activation of regulated transcription factors which induce new genes for late LTP (L-LTP). CaMK IV is also an important molecule for L-LTP which activates regulated transcription factors like CREB.

Stress-induced synaptic plasticity seems to result at least from activation of ERK1/2 pathway by stress (Yang et al., 2004). Yang et al. (2004) showed that stress-induced suppression of LTP and enhancement of LTD in the CA1 was blocked by pretreatment with GR antagonist, 11β, 17β-1[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4-9-dien-3-one. Further, this stress effect in LTP and LTD was blocked by specific inhibitors of MEK1/2, protein kinase C, tyrosine kinase, and BDNF antisense oligonucleotides, suggesting the involvement of corticosterone-induced sustained activation of ERK1/2-coupled signaling cascades in the stress effect on LTP and LTD.

CREB is also involved in the regulation of numerous types of synaptic changes in the hippocampus, amygdala, and cortex. Since stress and mood stabilizers are known to regulate these signaling pathways involved in the mediation of LTP, it is conceivable that stress-induced synaptic alterations can be remedied by the treatment with mood stabilizers. There is substantial evidence supporting this notion.
Lithium by itself facilitates LTP in hippocampal subregions. Chronic treatment with lithium (28 days) (Nocjar et al., 2007) and subchronic treatment with lithium (14 days) enhanced LTP in the CA1 and in the dentate gyrus (Shim et al., 2007), respectively. Lithium is believed to regulate signaling cascades mediating the induction of LTP (Shim et al., 2007). Son et al. (2003) showed that acute and chronic lithium treatment enhanced LTP in the dentate gyrus of the rat. They argued that LTP enhancing effect of lithium was mediated through upregulation of signaling molecules like BDNF, phosphorylated MAPK, phosphorylated CREB, CaMK II, phosphorylated Elk, and TrkB, but not through increased neurogenesis. Silva et al. (2008) showed that lithium prevented chronic mild stress-induced upregulation GSK-3β and downregulation of its downstream molecules bcl-2 associated athenogenes-1 and synapsin-I. Lithium also blocked depressive-like behavior resulting from chronic mild stress via inhibition of GSK-3β. A study showed that acute immobilization stress impaired LTP induction in the CA1 region, which was restored by addition of lithium of therapeutic concentration to artificial CSF in brain slices. However, the addition of lithium to slices from non-stressed animals had no effect (Lim et al., 2005).

5. The protective effect of mood stabilizers against stress-induced apoptosis and molecular changes

As mentioned above, exposure to stress results in increase in proapoptotic molecules and decrease in antiapoptotic molecules in laboratory animals (for review, see Kubera et al., 2011). On the other hand chronic stress reduces the expression of cell surviving molecules such as bcl-2 family antiapoptotic proteins, bcl-2 and BAG-1, brain derived neurotrophic factor (BDNF), and vascular growth factor (VGF) (Nair et al., 2007; Thomas et al., 2007). It is well known that primary mood stabilizers, lithium and valproate, increase antiapoptotic proteins of bcl-2 family such as bcl-2 and bcl-xl. In addition, chronic stress activates proinflammatory cytokines and induces neuroinflammatory changes (Kubera et al., 2011). Increased apoptosis following chronic stress was observed in the hippocampal subregions and entorhinal cortex of the tree shrew (Lucassen et al., 2001).

Several previous studies suggest that mood stabilizers protect or counteract these stress-induced apoptosis or molecular changes. Bachis et al. (2008) demonstrated that chronic unpredictable mild stress for five weeks promoted neuronal apoptosis by demonstrating increased caspase-3 positive neurons in the rat cortex. This effect was reversed by treatment with desipramine. Given the fact that the most prominent mood stabilizers, lithium and valproate upregulate anti-apoptotic proteins like bcl-2 (G. Chen et al., 1999; R.W. Chen & Chuang, 1999) and suppress proapoptotic proteins, p53 and Bax (R.W. Chen & Chuang, 1999) and other anticonvulsant mood stabilizers share this neuroprotective property (X. Li et al., 2002), it is conceivable that mood stabilizers protect against stress-induced apoptosis or molecular changes.

Actually, several lines of evidence support this notion. Miller and Mathé (1997) reported that chronic lithium treatment attenuated c-fos mRNA induction by acute injection stress in the rat frontal cortex and hippocampus. The same group reported that chronic lithium treatment attenuated AP-1 DNA binding induction by acute restraint stress in the frontal cortex and hippocampus and CREB binding in the frontal cortex (Miller et al., 2007). In line with these findings, chronic stress-induced increase in CREB phosphorylation and CREB
transcriptional activity was reversed with concomitant chronic lithium treatment (Boer et al., 2008) and imipramine treatment (Boer et al., 2007).

Kosten et al. (2008) demonstrated that chronic stress reduced the expression of antiapoptotic protein genes (bcl-2 and bcl-xl) in the limbic brain, which was prevented by the treatment with different classes of antidepressant. They also showed that a major proapoptotic protein, Bax gene expression was repressed by fluoxetine. Lithium is also known to block chronic mild stress-induced depressive-like behavior. This blockade of depressive-like behavior is accompanied by prevention of mild stress-induced increase of GSK-3β and decrease in its downstream targets, BAG-1, and synapsin-1 (Silva et al., 2008). This finding suggests that neuroprotective action of lithium against chronic stress effect involves the suppression of GSK-3β.

6. Stress-induced neuroinflammatory reactions are likely to be prevented by mood stabilizers

Exposure to psychosocial stressors leads to increased proinflammatory molecules as well as behavioral or mood disturbances in humans and animals. Stress-induced depressive-like behavior is associated with increase in interleukin 1-β (IL-1β), tumor necrosis factor-α (TNF-α), IL-6, nuclear factor κB (NFκB), cyclooxygenase-2 (COX-2), expression of Toll-like receptors and lipid peroxidation in animals (Kubera et al., 2011). In humans, various chronic psychosocial stressors like burnout, low socioeconomic status, childhood adversity and maltreatment, and loneliness also affect adversely stress response and induce increase in proinflammatory molecules (Hansel et al., 2010). Increased level of proinflammatory cytokines was observed in patients with stress-related disorders like depression (Maes, 1995) and posttraumatic stress disorder (Hoge et al., 2009). Depressed and manic states in bipolar disorder are considered to be a proinflammatory state. A study about cytokine levels in euthymic bipolar patients suggested that proinflammatory state resolved in euthymic state (Guloksuz et al., 2010). On the other hand, antidepressant therapy decreases proinflammatory cytokines, IL-β, IL-6, and TNF-α (Kubera et al., 2011). This line of studies suggests that pathophysiology of bipolar disorder and stress effects share the mechanism leading to proinflammatory state.

Chronic stress-induced increase in proinflammatory cytokines is associated with anhedonia (decreased sucrose intake) in laboratory animals (Gripppo et al., 2005). Decrease in hippocampal IL-1 was observed following chronic stress and only chronic IL-1 injection caused the similar behaviors which were observed in animals exposed to chronic stress (Goshen & Yirmiya, 2009). There is evidence to support that IL-1β is a mediator of stress-induced behaviors (Badowska-Szalewska et al., 2009). A study suggested IL-1β activity is coupled to phospholipase A2 (PLA2) by showing inhibition of IL-1β activity with nonspecific PLA2 antagonist, quinacrine (Song et al., 2007). Besides, IL-β, TNF-α and NFκB increase in the brain after chronic stress (Gripppo et al., 2005; Gu et al., 2009; Madrigal et al., 2002; Madrigal et al., 2001). NFκB recognizes specific DNA sequences in the promoters of genes encoding proinflammatory factors including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) (Kubera et al., 2011). Stress also increases reactive oxygen species and iNOS (Madrigal et al., 2001; Olivenza et al., 2000).
On the other hand, it is known that chronic treatment with lithium, carbamazepine, and valproate at therapeutically relevant doses decrease arachidonic acid turnover and the level of COX-2 and prostaglandin E$_2$ (PGE$_2$) in the rat brain (Chang et al., 1996; Rao et al., 2008). Lithium and carbamazepine reduce the AP-2 binding activity, which leads to decreased transcription, translation and activity of arachidonic acid-specific and calcium dependent phospholipase A$_2$ (cPLA$_2$) (Bosetti et al., 2003; Rao et al., 2008), a PLA$_2$ isoform specific for release of arachidonic acid from membrane phospholipids of the brain, whereas valproate inhibits long chain acyl-CoA synthetase and thus decreases the arachidonic acid turnover (Rao et al., 2008). However, chronic treatment with lithium does not affect COX-1 or Ca$^{2+}$-independent PLA$_2$ (Bosetti et al., 2002). Chronic treatment with valproate also decreases DNA binding activity of NF$\kappa$B in the rat frontal cortex (Rao et al., 2007a). Chronic administration of lamotrigine, an effective mood stabilizer blocking the relapse of depressive episode, decreases the level of COX-2 protein and mRNA expression in the rat frontal cortex without affecting the protein level of PLA$_2$ (Lee et al., 2008).

In addition, decreased turnover by chronic treatment with mood stabilizers is associated with increased expression of bcl-2 and BDNF in the brain. Chronic deprivation of dietary essential n-3 polyunsaturated fatty acids results in bipolar disorder-like symptoms in rats (DeMar et al., 2006) and increased expression of cPLA$_2$ and COX-2 (DeMar et al., 2006; Rao et al., 2007b). Deprivation of essential n-3 polyunsaturated fatty acids also leads to decreased expression of phosphorylated CREB and BDNF mRNA and proteins (Rao et al., 2007c).

7. Mood stabilizers attenuate stress-induced oxidative stress

Chronic stress increases the level of oxidative stress. Lucca et al. (2009) reported that chronic stress increased thiobarbituric acid reactive substances (TBARS) in the brain, a parameter of increased oxidative stress. In line with this study, lithium and valproate reversed amphetamine treatment-induced elevation of TBARS and prevented hyperactivity in an animal model of mania (Frey et al., 2006). These studies suggest that mood stabilizers, lithium and valproate, share the capability to prevent stress-induced increase in oxidative stress and that this anti-oxidant effect may contribute to their therapeutic actions. Lithium and valproate at therapeutically relevant concentrations in humans inhibited glutamate-induced increase in intracellular free Ca$^{2+}$ concentration, lipid peroxidation, and protein oxidation in cultured rat cerebral cortical cells, which suggests that lithium and valproate inhibit glutamate-induced excitotoxicity by inhibiting oxidative stress (Shao et al., 2005).

8. Are mood stabilizers efficacious for treating traumatic stress-related disorders?

Experiences can modify gene functions without DNA sequence changes and these mechanisms are called epigenetic modification. Epigenetic modification encompasses DNA methylation and histone acetylation and methylation (Krishnan & Nestler, 2008). Deprivation of maternal care in rat pups resulted in increased methylation of promoter region of GR gene in the hippocampus (Tsankova et al., 2007), and thus repressed gene expression. Early maltreatment also led to lasting increased methylation and decreased expression of BDNF gene in the prefrontal cortex of adult rats (Roth et al., 2009). A human study reported the association of higher level of methylation in serotonin transporter promoter with increased...
risk to unresolved loss or other trauma among adoptees (van et al., 2010). In an animal model of posttraumatic stress disorder (PTSD), traumatized rats showed hypermethylation of BDNF gene in the dorsal CA1 with reduced expression of BDNF mRNA. However, decreased methylation of BDNF gene was observed in the CA3, which suggests region-specificity (Roth et al., 2011). Epigenetic modification is involved in stress-related disorders like depression, bipolar disorder, and PTSD (Mill & Petronis, 2007; Petronis, 2003). On the other hand, among mood stabilizers, valproate is a histone deacetylase (HDAC) inhibitor and HDAC is a direct target of valproate (Phiel & Klein, 2001). Neuroprotective action of valproate is associated with hyperacetylation of histone (Chuang, 2005). Valproate was found to produce DNA demethylation and hyperacetylation in glutamate transporter-1 gene promoter in cultured primary astrocytes (Perisic et al., 2010).

Fig. 1. Schematic representation of stress induced neural changes antistress effects of mood stabilizers. Abbreviations used: Bcl-2: B-cell leukemia/lymphoma-2; BDNF: brain-derived neurotrophic factor; VEGF: vascular endothelial growth factor; Bax: bcl-2-associated X protein; BAD: bcl-2-associated death protein; ROS: reactive oxygen species; PFC: prefrontal cortex; LTP: long-term potentiation; LTD: long-term depression; IL-1,6: interleukin-1,6; TNF-α: tumor necrosis factor-α; cPLA₂: cytosolic phospholipase A₂; COX-1,2: cyclooxygenase-1,2; NFkB: nuclear transcription factor kappa B; AA: arachidonic acid.

www.intechopen.com
Taken together, it is suggested that mood stabilizers, especially valproate might be efficacious for treating traumatic stress-related disorders like PTSD. A systemic review suggest that valproate can be effective for the treatment of PTSD by reducing hyperarousal, improving irritability, anger outburst, and mood although it remains that more double blind studies are needed (Adamou et al., 2007). Lamotrigine significantly suppressed stress responses to public speech including suppression of stress hormones such as growth hormones and cortisol (Makatsori et al., 2004).

9. Conclusion
We live in a world full of stress. Inescapable changes in our life styles are imposing tremendous stress on us. Stress profoundly affects morphology and functions of the brain which is the central organ mediating stress response (McEwen, 2004). In the mental health area, we are increasingly faced with heavy burden of stress-related mental disorders like depression and bipolar disorder. Even though bipolar disorder is a serious mental disorder, pharmacological treatment of bipolar disorder is not always satisfactory. Pathophysiology of bipolar disorder and the mechanism of therapeutic actions of mood stabilizers remain to be elucidated.

Stress effects on the brain i.e. altered structural plasticity, impaired neurogenesis, altered synaptic efficacy, accelerated apoptosis, cognitive impairment, and proclivity to neuroinflammation are mediated through overlapping cascades and molecules involved in cell survival and death. For example, exposure to chronic mild stress in mice produces cognitive impairment accompanied by increased proinflammatory cytokines and stress hormones, decreased BDNF, and enhanced cell damage (S. Li et al., 2008). Furthermore, mood stabilizers have capabilities to reverse stress-induced behavioral impairments. Chronic stress-induced spatial memory impairment is attenuated by chronic lithium treatment (Vasconcellos et al., 2003). Chronic or subchronic treatment with lamotrigine ameliorates behavioral parameters in stress-induced animal models of depression with concomitant restoration of stress-induced downregulation of neuroprotective proteins (N. Li et al., 2010; N. Li et al., 2011). Interestingly, protective effects against stress-induced deleterious effects on the brain (anti-stress effects) seem to be shared by most mood stabilizers. As described in the preceding sections, effects of stress are mediated through signaling cascades that are also the targets of mood stabilizers. In this context, mood stabilizing effects may be ascribed to anti-stress effects of mood stabilizers.

10. Acknowledgment
The authors would like to thank Dr. Jeewon Lee and Dr. Hye-won Baek for their contribution to the revision process of this article.

11. References


Bipolar Disorder – A Portrait of a Complex Mood Disorder


Anti-Stress Effects of Mood Stabilizers and Relevance to Their Therapeutic Actions


Bipolar Disorder – A Portrait of a Complex Mood Disorder


Anti-Stress Effects of Mood Stabilizers and Relevance to Their Therapeutic Actions


www.intechopen.com


www.intechopen.com


www.intechopen.com
Bipolar Disorder: Portrait of a Complex Mood Disorder is a step towards integrating many diverse perspectives on BD. As we shall see, such diversity makes it difficult to clearly define the boundaries of BD. It is helpful to view BD from this perspective, as a final common pathway arises from multiple frames of reference. The integration of epigenetics, molecular pharmacology, and neurophysiology is essential. One solution involves using this diverse data to search for endophenotypes to aid researchers, even though most clinicians prefer broader groupings of symptoms and clinical variables. Our challenge is to consolidate this new information with existing clinical practice in a usable fashion. This need for convergent thinkers who can integrate the findings in this book remains a critical need. This book is a small step in that direction and hopefully guides researchers and clinicians towards a new synthesis of basic neurosciences and clinical psychiatry.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
